Could a new PET tracer reveal hidden prostate cancer activity?

NCT ID NCT05242744

Recruiting now Diagnosis Sponsor: Abramson Cancer Center at Penn Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radioactive tracer called [18F]FluorThanatrace (FTT) used with PET/CT scans to measure PARP-1 activity in men with metastatic prostate cancer. Up to 30 participants will have scans before and after starting a new therapy. The goal is to see if FTT can non-invasively show PARP expression, which might help guide treatment decisions in the future.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [18F]FluorThanatrace (a radioactive tracer for PET scans)
What this could lead to: If successful, this could lead to a better way to see PARP activity in prostate cancer tumors using a simple scan, helping doctors choose the right treatments.
What could go wrong: This is a small, early-phase imaging study with only 30 participants. The tracer may not reliably show PARP activity in all patients, and it is not a treatment itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER METASTATIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER METASTATIC

Contacts and locations

Locations

University of Pennsylvania Hospital
RECRUITING

Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.